• FirefoxUpgrade to the new Firefox »
  •  Dow Down 0.79% Nasdaq Up 0.16%

    Theravance Inc. (THRX)

    -NasdaqGS
    11.78 Down 0.21(1.75%) Jan 23, 4:00PM EST
    |After Hours : 11.78 0.00 (0.00%) Jan 23, 4:31PM EST
    Add to Portfolio
    Prev Close:11.99
    Open:11.98
    Bid:10.10 x 100
    Ask:N/A
    1y Target Est:23.71
    Beta:1.17
    Earnings Date:Feb 4 - Feb 9 (Est.)
    Day's Range:11.43 - 12.13
    52wk Range:11.16 - 32.89
    Volume:1,011,022
    Avg Vol (3m):975,031
    Market Cap:1.36B
    P/E (ttm):N/A
    EPS (ttm):-1.83
    Div & Yield:0.50 (4.20%)
    Quotes delayed, except where indicated otherwise. Currency in USD.

    Comparison

    Symbol% ChgMkt Cap
    THRXDown 1.75%1.36B
    AZNUp 0.08%89.28B
    CBST 0.00%N/A
    PFEDown 1.10%204.46B

    Key Statistics

    Forward P/E (1 yr):N/A
    P/S (ttm):485.02
    Ex-Dividend Date:21-Nov-14

    Analysts

    Annual EPS Est (Dec-14) :-1.37
    Quarterly EPS Est (Dec-14) :-0.15
    Mean Recommendation*:3.0
    PEG Ratio (5 yr expected):0.05

    * (Strong Buy) 1.0 - 5.0 (Sell)

    Analyst Opinion | Estimates

    Business Summary

    Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and ... View More
    Your browser doesn't support canvas
    SETTINGS
    Scrolling
    Speed
    Display
    Price
    Submit Feedback